Marker Therapeutics (NASDAQ:MRKR) Now Covered by Analysts at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH assumed coverage on shares of Marker Therapeutics (NASDAQ:MRKR) in a report published on Tuesday morning, Benzinga reports. The firm issued a buy rating and a $11.00 target price on the stock.

Marker Therapeutics Stock Down 2.1 %

Marker Therapeutics stock traded down $0.09 during mid-day trading on Tuesday, reaching $4.11. 13,189 shares of the company were exchanged, compared to its average volume of 19,919. Marker Therapeutics has a 12-month low of $1.16 and a 12-month high of $9.68. The business has a fifty day moving average of $4.29 and a 200 day moving average of $3.98.

Hedge Funds Weigh In On Marker Therapeutics

A hedge fund recently raised its stake in Marker Therapeutics stock. International Assets Investment Management LLC raised its position in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) by 1,000.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 11,000 shares of the company’s stock after purchasing an additional 10,000 shares during the quarter. International Assets Investment Management LLC owned 0.12% of Marker Therapeutics worth $60,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells.